Standard BioTools Inc. Proceeds from Notes Payable
Standard BioTools Inc. (LAB) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2014-03-12
- Standard BioTools Inc. proceeds from notes payable for the quarter ending 2012-12-31 was $0.00.
- Standard BioTools Inc. proceeds from notes payable for the quarter ending 2012-09-30 was $0.00.
- Standard BioTools Inc. proceeds from notes payable for the quarter ending 2011-12-31 was $0.00.
- Standard BioTools Inc. proceeds from notes payable for the quarter ending 2011-09-30 was $0.00.
- Standard BioTools Inc. proceeds from notes payable for fiscal 2013 was $0.00.
- Standard BioTools Inc. proceeds from notes payable for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Standard BioTools Inc. proceeds from notes payable for fiscal 2011 was $5.00M.
- Standard BioTools Inc. proceeds from notes payable for fiscal 2010 was $0.00.
| Period end | Proceeds from Notes Payable 1 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-12 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $0.00 derived: sum of 2 quarters · filed 2014-03-12 | $0.00 10-K · filed 2014-03-12 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $0.00 derived: sum of 2 quarters · filed 2014-03-12 | $0.00 derived: sum of 3 quarters · filed 2014-03-12 | $5.00M 10-K · filed 2014-03-12 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $5.00M 10-Q · filed 2012-11-09 | $5.00M derived: sum of 4 quarters · filed 2013-03-12 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $5.00M 10-Q · filed 2012-08-14 | $5.00M derived: sum of 3 quarters · filed 2013-03-12 | $5.00M derived: sum of 4 quarters · filed 2013-03-12 | |
| 2011-03-31 | $5.00M 10-Q · filed 2012-05-15 | $5.00M derived: sum of 2 quarters · filed 2013-03-12 | $5.00M derived: sum of 3 quarters · filed 2013-03-12 | ||
| 2011-01-31 | $5.00M 10-K · filed 2014-03-12 | ||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $0.00 derived: sum of 2 quarters · filed 2013-03-12 | $0.00 10-K · filed 2013-03-12 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | ||||
| 2009-12-31 | $0.00 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |